Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialHuabin Hu, Yanhong Deng, Liang Kang et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 304
Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL TrialHuabin Hu, Yanhong Deng, Kefeng Ding et al.|Journal of Clinical Oncology|2024Cited by 76
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with <i>RAS</i>/<i>BRAF</i> Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II TrialHuabin Hu, Yanhong Deng, Kun Wang et al.|The Oncologist|2020Cited by 50
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal CancerJianwei Zhang, Yanhong Deng, Meijin Huang et al.|Clinical Colorectal Cancer|2019Cited by 41
Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal CancerJianxia Li, Yanhong Deng, Huabin Hu et al.|Clinical Cancer Research|2023Cited by 33